Browse Articles

Discover research articles across all indexed journals

Efficacy and safety of tislelizumab (T) combined with gemcitabine and cisplatin (GC) for patients with localized muscle-invasive bladder cancer (MIBC) after radical transurethral resection of bladder tumor/partial cystectomy: A prospective, phase II study.

Journal of Clinical Oncology Ming Cao, Dongdong Xiao, Wei Xue Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.784

784 Background: Transurethral resection of bladder tumor (TURBT) combined with concurrent chemoradiotherapy is the standard treatment for bladder preservation in MIBC. TURBT alone and partial cystectomy are only suitable for selected patients with solitary tumors, T2, and tumors in the bladder diverticulum while patients could have tumor recurrence after surgery. This prospective phase II study aims to explore the efficacy and safety of T combined with GC after radical TURBT or partial cystectomy as bladder preservation therapy in patients with PD-L1 positive MIBC. Methods: Eligible patients had clinical stage T2-T3N0M0, histologically confirmed PD-L1 positive urothelial carcinoma, no prior systemic treatment, and no residual tumor after radical TURBT or partial cystectomy. Patients received T combined with GC within 8 weeks of local treatment (G 1000mg/m2, d1, d8; C 70mg/m2, d1, IV, q3w, for a total of 6 cycles. T 200mg, d8, IV, q3w, for a total of 8 cycles). The primary endpoint was 1-year bladder intact disease-free survival rate. Secondary endpoints included 2-year bladder intact disease-free survival rate, metastasis-free survival, time to salvage cystectomy, overall survival, and safety. Results: From August 2022 to October 2024, a total of 13 patients were enrolled in the study. Median age was 70 years (65-75). Twelve patients were staged as pT2 and 1 patient had pT3. Twelve patients were evaluable for efficacy and 1 patient withdrew the consent. Seven patients underwent TURBT and 5 patients underwent partial cystectomy. Median follow-up time was 8.0 months. One patient had non-muscle-invasive bladder cancer recurrence and receive intravesical BCG instillation while the remains had no recurrence of disease. 1-year bladder-intact disease-free survival rate was 100%. Grade 3 or higher adverse events occurred in 33.3% of patients. No new safety signals were observed. Conclusions: The study demonstrated that combination of T and GC after complete resection of tumor seemed promising as bladder preservation strategy in selected patients. Further recruitment is ongoing. Clinical trial information: NCT05401279 .

Frailty and adverse clinical outcomes in prostate cancer patients: An analysis from the RADICAL-PC cohort.

Journal of Clinical Oncology Rocio Consuelo Baro Vila, Jehonathan H. Pinthus, Sarah Karampatos et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.80

80 Background: As a disease of older individuals, prostate cancer (PC) may feature physical frailty. Most related studies are retrospective and focus on short-term surgical outcomes. Methods: We conductedan analysis of a prospective study of PC patients either diagnosed within the past year, treated with androgen deprivation therapy (ADT) for the first time within the past six months, or scheduled to initiate ADT within a month . Frailty was assessed using Fried's criteria which includes five domains [Handgrip strength, gait speed, physical activity, unintentional weight loss (>4 kg/year) and exhaustion (≥3 days/week)]. Patients were classified as frail (≥3 criteria), pre-frail (1-2 criteria), or robust (0 criteria). Participants were followed annually to ascertain the occurrence of mortality, new metastases, major adverse cardiovascular events (MACE: myocardial infarction, stroke, cardiovascular death, stroke, heart failure, peripheral arterial disease, venous thromboembolism or arterial revascularization) and hospitalization. The relationship between frailty and these events was evaluated by Cox proportional hazards models adjusted for age at enrolment, education, race, tobacco and alcohol use, diabetes, past history of cardiovascular disease, estimated glomerular filtration rate, PC risk, metastatic disease and ADT exposure. Results: We studied 4304 participants (mean age 69±8 years) from 9 countries: 1429 (33%) were robust, 2394 (56%) pre-frail and 481 (11%), frail. During a median 2.4 years, 336 (8%) died, 161 (4%) died from PC or developed new metastases, 506 (12%) were hospitalized and 262 (6%) experienced MACE. Being prefrail or frail was associated with a higher risk of death, hospitalization and MACE but not PC death or new metastases (Table). Conclusions: Pre-frailty and frailty are common among patients with PC. Frailty is associated with approximately a two-fold increase in mortality, hospitalization or MACE in PC patients independent of a wide range of prognostic factors. Relationship between frailty and clinical outcomes. Characteristic Death Hospitalization PC death or new metastases MACE Hazard ratio (95% confidence interval) p-value Hazard ratio (95% confidence interval) p-value Hazard ratio (95% confidence interval) p-value Hazard ratio (95% confidence interval) p-value Frailty Robust Pre-frail Frail Ref1.54(1.13-2.00)2.90(2.00-4.21) 0.007<0.001 Ref1.39(1.10-1.74)2.29(1.70-3.09) 0.005<0.001 Ref1.05(0.70-1.57)1.47(0.85-2.52) 0.830.17 Ref1.44(1.05-1.97)2.21(1.46-3.34) 0.023<0.001 Estimates are from Cox proportional hazards models adjusted for age at enrolment, education, race, tobacco and alcohol use, diabetes, past history of cardiovascular disease, estimated glomerular filtration rate, PC risk, metastatic disease and ADT exposure.

Reflexive paired somatic and germline testing at time of medical oncology referral in mCSPC: Impact on timely treatment.

Journal of Clinical Oncology Richard Gagnon, Emma Hoag, Alexandra Olsen et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.62

62 Background: Use of PARP inhibitors (PARPi) improves outcomes in patients with metastatic castrate-resistant prostate cancer (mCRPC) harboring germline or somatic homologous recombination repair (HRR) mutations. To ensure timely PARPi initiation, genetic results should be available at castrate resistance, with testing initiated in the metastatic castration-sensitive (mCSPC) setting. Relying on ad hoc, provider-initiated testing risks biomarker unavailability when treatment decisions are made, leading to suboptimal therapies. This study evaluates a program of reflexive paired germline and tumor testing for mCSPC patients at medical oncology referral (typically following initial management and androgen deprivation therapy [ADT] by urology or radiation oncology) as a potentially effective time point for genetic testing. Methods: This was a single cancer centre, retrospective review of mCSPC patients offered simultaneous germline and tumor tissue next-generation sequencing at medical oncology referral. We examined test completion rates, timing of results relative to key disease timepoints (ADT initiation, first-line mCRPC treatment), and the frequency of detected pathogenic mutations. Timing of results was analyzed separately for all patients, those with HRR mutations, and those with timely referrals to medical oncology, defined as <90 days from ADT start. Results: Of 218 mCSPC patients, 212 (97.2%) completed germline or tumor tissue sequencing with interpretable results from at least one assay. Germline results were obtained in 171 patients (78.4%) and tumor tissue results in 194 (88.9%). HRR mutations were detected in 29 patients (13.3%): 15 germline, 10 somatic, and 4 of unknown origin. Median time from ADT initiation to germline and tumor tissue genetic results was 165 and 120 days, respectively. Germline results were available for 144 patients (84.2%) and tumor tissue results for 176 (90.7%) before initiation of first-line mCRPC treatment. Among the 29 patients with identified HRR mutations, 19 (76%) had germline results and 17 (81%) had tumor tissue results before first-line mCRPC treatment. In the subgroup of 175 patients referred to medical oncology within 90 days of ADT initiation, 136 patients (98.6%) had germline results and 148 (99.3%) had tumor tissue results before first-line mCRPC treatment. Conclusions: Reflexive paired genetic testing at medical oncology referral is effective in identifying HRR mutations and optimizing PARPi use based on current mCRPC indications. Ensuring timely patient identification through clear and accessible genetic testing pathways will help maximize therapeutic options for patients with advanced prostate cancer. If PARPi or other targeted agents demonstrate benefit in earlier disease states, this process may need to be shifted further upstream, requiring close multidisciplinary collaboration.

A cosmogenic 10Be anomaly during the late Miocene as independent time marker for marine archives

Nature Communications Dominik Koll, Johannes Lachner, Sabrina Beutner et al. Feb 10, 2025 DOI: 10.1038/s41467-024-55662-4

Abstract Cosmogenic nuclide dating relies on the constancy of production and incorporation of radionuclides in geological archives. Anomalous deviations from constancy during the Holocene or Pleistocene are frequently used as global benchmarks to harmonize different data sets. A similar dating anchor on the million year timescale was so far not presented. In this work, we report on a prolonged cosmogenic 10Be anomaly during the late Miocene recorded in several Central and Northern Pacific deep-ocean ferromanganese crusts in the time period 9–11.5 Myr ago peaking at 10.1 Myr. Potential origins of this anomaly are discussed in the light of geological, climatic, solar and astrophysical events. This anomaly has the potential to be an independent time marker for marine archives.

PERSIAN trial: Early results from a randomized phase II trial testing apalutamide and stereotactic body radiation therapy for low-burden, metastatic, hormone-sensitive prostate cancer.

Journal of Clinical Oncology Giulio Francolini, Vanessa Di Cataldo, Pietro Garlatti et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.160

160 Background: Apalutamide+androgen deprivation therapy (ADT) showed to significantly improve overall survival in low and high volume metastatic hormone sensitive prostate cancer (mHSPC) if compared to ADT alone. However, a randomized phase II trial (ARTO, NCT03449719) suggested that stereotactic body radiotherapy (SBRT) improved clinical outcomes when administered concomitantly with abiraterone acetate in metastatic castration resistance prostate cancer (mCRPC). Nonetheless, evidence related to use of SBRT in addition to androgen receptor pathway inhibitors (ARPIs) in oligometastatic HSPC is currently lacking. PERSIAN trial is aimed to test the hypothesis that metastases directed SBRT will improve outcomes in selected subgroups of patients with oligometastatic mHSPC treated with apalutamide + ADT. Methods: PERSIAN NCT05717660 is a phase II randomized trial enrolling patients affected by metachronous oligometastatic HSPC. Patients with de novo metastatic disease or with > 5 distant metastases are excluded from the trial. All patients are randomized to standard of care with apalutamide+ADT (ARM A: Control) or the same systemic treatment combined with SBRT on all sites of metastatic disease evidenced on conventional imaging (ARM B: Treatment). Here is presented the first interim analysis focused on rate of complete biochemical response (PSA < 0.2 ng/ml) after 3 months since apalutamide + ADT start. Results: Up to date, 174 patients have been enrolled (96.6% of the target sample size), 87 of these reached a minimum follow up of 3 months. Rate of patients with a complete biochemical response was 91.1% vs 92.9% in the control vs treatment arm, respectively (OR 1.27, 95% CI 0.27-6.03, p=0.765). Patients with PSMA positive lesions undetected on conventional imaging vs patients in whom number of target lesions was consistent on conventional and PSMA imaging had similar results (OR 0.74, 95%CI 0.08-6.94, p=0.791). Presence of bone metastatic lesions did not influence rate of complete biochemical response (OR 1.39, 95%CI 0.29-6.67, p-value 0.678). When adjusted for number of lesions, a significant benefit in favour of experimental arm was detected for patients with <3 metastatic sites (OR 5.88, 95%CI 1.13-33.3, p=0.03). Conclusions: Rate of early complete biochemical response showed a non significant trend in favour of experimental arm, with a 27% odds increase in the overall population for patients undergoing SBRT. Clinical benefit of SBRT is significantly improved in patients with lower burden of disease (<3 metastatic lesions). Trial accrual will be completed within the end of 2024, early results about complete biochemical response at 6 months in the complete cohort will be available in the second half of 2025. Clinical trial information: NCT03449719 .

Evaluating an integrated germline polygenic and clinical risk model (P-CARE) specifically for aggressive prostate cancer.

Journal of Clinical Oncology Anna Dornisch, George Xu, Roshan Karunamuni et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.237

237 Background: Polygenic scores are strongly associated with age at diagnosis of prostate cancer (PCa) but have not been clearly shown to discriminate between indolent and aggressive PCa. P-CARE (Prostate CAncer integrated Risk Evaluation) is an integrated model that combines a 601-variant polygenic hazard score (PHS601), genetic ancestry, and family history. We hypothesize that among men diagnosed with PCa, those with higher P-CARE scores are more likely to develop metastatic disease. Methods: We analyzed genetic and phenotypic data from a diverse, national cohort of men diagnosed with PCa (Million Veteran Program, n=69,901, 6413 metastatic). We used Cox proportional hazards models to test P-CARE and PHS601 for association with age at onset of metastatic PCa (birth-met analysis). We also tested P-CARE for association with metastasis-free survival after diagnosis of localized PCa, with or without accounting for PSA, stage, and age at diagnosis (localized-met analysis). PCa was detected/treated too late if the patient had definitive treatment for localized disease but developed metastasis. Thus, onset of metastasis was time of first treatment or diagnosis of metastasis, whichever occurred first. Participants who never experienced metastasis were censored at time of first treatment or last follow-up/death.We repeated this analysis within men with African genetic ancestry (n=16,889). Confidence intervals for hazard ratios (HR) were estimated using 100-fold bootstrapping. For external validation of direction of effect, we tested P-CARE for association with age at diagnosis of clinically significant PCa in cohorts from the PRACTICAL Consortium (Cohort of Swedish Men [COSM, n=2163], ProtecT [n=1583]). Results: P-CARE was associated with birth-met and localized-met in the full MVP cohort and among men with African ancestry. In the full cohort, patients in the highest 20% of P-CARE (based on percentiles of men of European ancestry with PCa) compared with the lowest 20% had a HR (HR 80/20 ) of 1.58 [95% CI 1.48–1.68] and 1.32 [1.23–1.40] for birth-met and localized-met, respectively. The corresponding HR 80/20 values for PHS601 alone were 1.29 [1.20–1.37] and 1.16 [1.07–1.25]. When accounting for PSA, stage, and age at diagnosis, P-CARE HR 80/20 was 1.05 [0.99-1.11] for localized-met. Among men with African ancestry, HR 80/20 was 1.43 [1.26–1.62] and 1.17 [1.03–1.34] for birth-met and localized-met, respectively. Within the PRACTICAL cohorts, P-CARE was associated with development of clinically significant PCa (COSM: 1.33 [1.16–1.57], ProtecT: 1.67 [1.34–2.10]). Conclusions: Among men diagnosed with PCa, P-CARE and PHS601 are moderately specific for metastatic disease. We are currently studying P-CARE in ProGRESS (ClinicalTrials.gov ID NCT05926102), a nationwide randomized clinical trial to evaluate precision PCa screening in the VA healthcare system.

A phase 2 study of neoadjuvant PARP inhibition followed by radical prostatectomy (RP) in patients with unfavorable intermediate-risk or high-risk prostate cancer with <i>BRCA1/2</i> gene alterations (NePtune).

Journal of Clinical Oncology Yu-Wei Chen, Lin Liu, Yuwei Cheng et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.tps430

TPS430 Background: Patients with localized high-risk prostate cancer face an elevated risk of recurrence after radical prostatectomy (RP). Approximately 6% of these patients carry germline mutations in DNA repair pathways, most commonly involving BRCA1/2 genes. These mutations are linked to more aggressive disease, a higher likelihood of distant metastasis, and worse survival outcomes compared to those without them. Olaparib, a PARP inhibitor, has improved overall survival in metastatic castration-resistant prostate cancer with BRCA1/2 germline or somatic mutations. Additionally, olaparib has shown efficacy as adjuvant therapy in improving invasive disease-free survival in patients with germline BRCA1/2 mutations and HER2-negative breast cancer. Multimodal treatment strategies for high-risk localized prostate cancer patients with BRCA1/2 mutations, whether germline or somatic, may improve clinical outcomes. Methods: We initiated a multicenter, phase 2, single-arm study to evaluate neoadjuvant olaparib combined with an LHRH agonist for 6 months, followed by radical prostatectomy (RP). Eligible patients include those with a Gleason score ≥4+3=7, PSA &gt;20 ng/mL, or T3 disease (determined by DRE or prostate MRI) with lymph nodes &lt;20 mm. Patients with intraductal carcinoma are eligible regardless of Gleason score, PSA level, or T stage. All participants must have germline or somatic BRCA1/2 pathogenic or likely pathogenic alterations identified through standard of care molecular profiling. Eligible patients will receive olaparib 300 mg orally twice daily along with an LHRH agonist for 6 months before undergoing RP. The primary endpoint is the rate of pathologic complete response (pCR) or minimal residual disease (MRD, defined as tumor ≤5 mm) as assessed by central pathology review. Secondary endpoints include PSA response, surgical staging at RP, positive margin rate, time to testosterone recovery, and safety. Exploratory endpoints include quality of life assessments, the proportion of downstaging observed on multiparametric MRI (mpMRI), correlation of mpMRI findings with pathologic response, and tissue-based molecular predictors of response and resistance. Sample size was calculated using a Binomial Exact test to evaluate the null hypothesis of a pCR/MRD rate ≤10% at a one-sided 5% significance level. Assuming an observed rate of ≥32.5% in this study, to conclude that the pCR/MRD rate is above 10% with 90% power, a total of 30 patients will be enrolled. At least 7 responses are needed to reject the null hypothesis. This trial is enrolling through the Hoosier Cancer Research Network, with active sites at the University of California San Diego, University of Pennsylvania, Johns Hopkins Hospital, Memorial Sloan Kettering Cancer Center, Columbia University, and the University of Buffalo. Clinical trial information: NCT05498272 .

Impact of pre-existing diabetes mellitus on acute care use in older patients with metastatic prostate cancer on androgen receptor signaling inhibitors.

Journal of Clinical Oncology Michael A. Liu, Rohit R. Raghunathan, Karie Runcie et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.119

119 Background: Androgen receptor signaling inhibitors (ARSIs) are mainstay treatments for metastatic prostate cancer. Hyperglycemia is a common side effect but limited data exists on outcomes such as hospitalizations in patients with diabetes mellitus (DM) starting on ARSIs. Methods: We used the SEER-Medicare linked data for patients aged 66 and older with de novo metastatic prostate cancer who were prescribed abiraterone, enzalutamide, or apalutamide per part D files from 2011 to 2019. Eligible patients had continuous Medicare Part A/ B coverage before and after drug initiation, and Part D coverage before initiation. Patients were excluded if they died within 6 months of diagnosis or received chemotherapy prior to ARSI (&lt;1%). Univariate associations between covariates and DM were assessed using chi-square tests or t-tests. Negative binomial regression was used to calculate incidence rate ratios of acute care use (total number of hospital or emergency admissions divided by total time at risk) for each model covariate among DM and non-DM patients after initiation of ARSI. Results: 2697 patients met eligibility criteria, of which 17.4% (469) had DM. The average age of the cohort was 75.0 years ±7.0 SD. 85.3% (2300) of patients received androgen deprivation therapy (ADT) prior to ARSI, and 0.9% (24) received ADT afterwards. 28.3% (773) of patients received abiraterone only, 23.8% (641) received only enzalutamide or apalutamide, and 47.6% (1283) received both treatments. Patients with DM (vs without) differed significantly with regards to lower high school education, higher NCI comorbidity score (excluding DM), and less receipt of abiraterone, but not in age, race, marital status, prior ADT treatment, or receipt of enzalutamide or apalutamide. 29.5% (797) of patients had acute care use within 6 months, with 39.9% (187) in the DM group and 27.4% (610) in the non-DM group ( p &lt;.0001), Adjusted for covariates, patients with DM had a 41% increased rate of acute care use ( p =0.0016) compared to those without DM. Additionally, compared to those prescribed only enzalutamide or apalutamide, patients prescribed abiraterone had a 47% increased rate of acute care use ( p =0.0026); this was independent of having DM (interaction p =0.77). Conclusions: Patients with pre-existing DM on ARSIs experienced higher rates of acute care use compared to those without DM, regardless of ARSI type. Future studies should assess potential interventions in older patients with diabetes on ARSIs, such as close monitoring of glycemic status or adherence to risk reduction medications.

Laser-driven proton acceleration beyond 100 MeV by radiation pressure and Coulomb repulsion in a conduction-restricted plasma

Nature Communications Yinren Shou, Xuezhi Wu, Ki Hong Pae et al. Feb 10, 2025 DOI: 10.1038/s41467-025-56667-3

KEYMAKER-U03 Substudy 03B: Pembrolizumab (pembro) and targeted therapy combinations for advanced clear cell renal cell carcinoma (ccRCC).

Journal of Clinical Oncology Laurence Albiges, Cristina Suarez, Thomas Powles et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.440

440 Background: The phase 1/2 KEYMAKER-U03 Substudy 03B (NCT04626518) is being conducted to evaluate combination treatments for previously treated advanced ccRCC. We present results for targeted therapy–containing regimens from arm B4 (pembro + belzutifan [HIF-2α inhibitor]), arm B5 (lenvatinib [VEGF-TKI] + belzutifan), and the reference (ref) arm (pembro + lenvatinib). Methods: Adults with histologically confirmed locally advanced/metastatic ccRCC and disease progression on or after PD-(L)1 inhibitor and VEGF-TKI treatment were randomly assigned 1:1 to arms open for enrollment. Arms B4 and B5 had a safety lead-in phase where ~10 patients (pts) were initially enrolled before randomization. Treatment doses were pembro 400 mg IV Q6W + belzutifan 120 mg PO QD (arm B4), lenvatinib 20 mg PO QD + belzutifan 120 mg PO QD (arm B5), or pembro 400 mg IV Q6W + lenvatinib 20 mg PO QD (ref arm). Primary end points were safety and ORR per RECIST v1.1 by blinded independent central review (BICR). Secondary end points included DOR, clinical benefit rate (CBR; CR + PR + SD ≥6 months), and PFS per RECIST v1.1 by BICR, and OS. Efficacy was evaluated in all enrolled (allocated and randomized) pts; safety was evaluated in all pts who received ≥1 dose of treatment. No formal comparisons across arms occurred. Enrollment was planned for 50 pts in each arm, although enrollment would be stopped if the 6-mo PFS rate was ≤40%. Results: Overall, 62 pts were assigned to arm B4, 64 to arm B5, and 73 to the ref arm. Median (range) follow-up was 16.6 mo (6.5-38.7) in arm B4, 17.6 mo (6.5-35.9) in arm B5, and 19.4 mo (6.7-33.2) in the ref arm. Efficacy is reported in the table. Grade 3-5 treatment-related AEs (TRAEs) occurred in 26/62 pts (42%) in arm B4, 38/63 pts (60%) in arm B5, and 36/73 pts (49%) in the ref arm. TRAEs led to death in 2 pts in arm B5 (cerebral hemorrhage and intracranial hemorrhage) and 1 pt in the ref arm (esophageal perforation). Conclusions: Lenvatinib + belzutifan (arm B5) exhibited durable antitumor activity and a safety profile consistent with the individual profiles of the drugs. Results from Substudy-03B support further investigation of lenvatinib + belzutifan combination for pts with advanced RCC, as in LITESPARK-011. Clinical trial information: NCT04626518 . Arm B4Pembro + belzutifann = 62 Arm B5Lenvatinib + belzutifann = 64 Ref armPembro + lenvatinibn = 73 ORR (95% CI), % 19 (10-31) 47 (34-60) 40 (29-52) CR, n (%) 2 (3) 1 (2) 0 (0) PR, n (%) 10 (16) 29 (45) 29 (40) CBR (95% CI), % 32 (21-45) 59 (46-72) 58 (45-69) DOR, median (range), mo Not reached (1.4+-33.0+) 22.1 (1.4+-32.8+) 8.3 (2.6+-25.6+) PFS, median (95% CI), mo 5.4 (2.8-6.9) 12.5 (5.9-26.3) 9.4 (6.9-11.2) 6-mo PFS rate, % 42 63 67 OS, median (95% CI), mo 27.4 (12.6-not reached) 32.3 (22.4-not reached) Not reached (21.8-not reached) 12-mo OS rate, % 68 80 82

Racial disparities in secondary metastasis in patients with bladder cancer: A 5-year National Inpatient Sample study.

Journal of Clinical Oncology Sakditad Saowapa, Natchaya Polpichai, Manasawee Tanariyakul et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.671

671 Background: Bladder cancer is one of the most common cancers globally, with significant variations in disease outcomes observed across racial groups. Secondary metastasis plays a critical role in determining disease prognosis and overall survival in bladder cancer patients. However, racial disparities in the metastatic progression of bladder cancer remain underexplored. This study aims to investigate how race influences the patterns of metastasis in bladder cancer patients using a large national database. Methods: A retrospective analysis of the National Inpatient Sample (NIS) from 2016 to 2020 was performed to identify adults diagnosed with bladder cancer using ICD-10 codes. Patients were categorized based on the presence of metastasis. Multivariable logistic regression models were used to assess the impact of race on secondary metastasis to key organ systems, including the lung, liver, bone, and brain, while adjusting for potential confounders. Caucasians were used as the reference group, and statistical significance was defined as p-values ≤ 0.05. Results: The study cohort included 411,360 patients with bladder cancer, of whom 66,805 (16.2%) had secondary metastasis. The mean age of patients with metastasis was significantly lower (71.00 years, 95% CI: 70.78–71.22) compared to those without metastasis (74.02 years, 95% CI: 73.90–74.14) (p &lt; 0.001). Racial disparities were observed, with African American patients having higher odds of lung metastasis (OR 1.23, 95% CI: 1.11–1.38, p &lt; 0.001) and liver metastasis (OR 1.18, 95% CI: 1.05–1.33, p = 0.005). Asian patients were more likely to develop bone metastasis (OR 1.29, 95% CI: 1.13–1.47, p &lt; 0.001) and brain metastasis (OR 1.46, 95% CI: 1.03–2.09, p = 0.036). Other factors associated with higher metastasis risk included radiation therapy (OR 3.71, 95% CI: 2.16–6.38, p &lt; 0.001), while comorbidities like diabetes (OR 0.64, p &lt; 0.001) and hypertension (OR 0.86, p &lt; 0.001) were associated with lower odds of metastasis. Conclusions: This study highlights significant racial disparities in the metastatic progression of bladder cancer, with African American and Asian patients showing higher odds of metastasis to key organ systems compared to Caucasians. These findings underscore the need to consider racial differences in the clinical management and treatment strategies for bladder cancer patients. Further research is required to explore the underlying causes of these disparities and their impact on long-term survival.

Evaluating the efficacy of cabozantinib in patients with advanced renal cell carcinoma with bone metastasis: An open-label phase 2 study.

Journal of Clinical Oncology Fumiya Hongo, Yasutomo Nakai, Masahiro Nozawa et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.535

535 Background: Bone metastasis negatively impacts patients with advanced renal cell carcinoma (aRCC), leading to poor prognosis and quality of life. Some tyrosine kinase inhibitors, including cabozantinib, have been used as standard care for aRCC. However, there have been no reports demonstrating the effects of cabozantinib on bone metastasis. Here, we report the clinical effects of cabozantinib on bone metastasis in patients with aRCC. Methods: Patients with aRCC who had at least one measurable bone target lesion were enrolled. Patients received cabozantinib 60 mg once daily until disease progression or intolerable toxicity. The primary endpoint was objective response rate (ORR) of bone target lesions based on independent review committee (IRC) assessment using the MD Anderson Cancer Center (MDA) criteria, which are the response criteria specific to bone metastases. Key secondary endpoints included disease control rate (DCR), bone metastasis-free survival (BMFS), progression-free survival (PFS), overall survival (OS), frequency of symptomatic skeletal events (SSE) and safety. Results: In total, 31 patients were enrolled, with a median age of 70.0 years, and most patients (77.4%) had a history of systemic treatments for aRCC. All patients had bone metastasis. The ORR of bone target lesions by IRC-assessed MDA criteria was 6.5% (90% CI: 1.2–18.9), with a disease control rate (DCR) of 90.3% (90% CI: 76.8–97.3). No progressive disease was observed. The median BMFS was not reached (95% CI: 11.5–NR). The median PFS and OS were 11.9 (95% CI: 5.7–NR) months and 24.9 (95% CI: 19.1–NR) months, respectively. Three patients (9.7%) experienced SSE. No new safety concerns were identified. Conclusions: Cabozantinib demonstrated favorable clinical effects on bone metastasis in patients with aRCC, as suggested by a high DCR. Our results may provide useful insights for selecting optimal treatments for the management of aRCC with bone metastasis. Clinical trial information: jRCTs031210220 .

<i>FGD1</i> splice variants as predictors of brain and bone metastatic organotropism in clear cell renal cell carcinoma.

Journal of Clinical Oncology Justin Miller, Alyssa N Obermayer, Mitchell T. Hayes et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.577

577 Background: Approximately 30% of patients with ccRCC present with metastatic disease (stage IV) and close to half of patients with stage III disease will recur during follow-up surveillance. Two of the most common and morbid sites of metastatic development are brain and bone metastasis. Existing treatment guidelines do not recommend routine brain or bone directed imaging during either initial staging or surveillance in the absence of clinical signs or symptoms. A group of recurrently altered aberrant splice variants in primary ccRCC tumors associated with metastatic progression have previously been identified. Our study aims to investigate metastatic organotropism of the FGD1 -splice variant ( FGD1 -SV) to refine risk stratification and therapeutic decision-making as cabozantinib is drug with activity at these disease sites. Methods: This study leveraged the ORIEN AVATAR network, a data-sharing alliance of 18 NCI-designated cancer centers, to evaluate the presence of FGD1 -SV in a cohort of 1,001 clear cell renal cell carcinoma (ccRCC) patients using bulk RNA-sequencing (RNA-seq). Samples with three or more FGD1 -SV reads were classified as positive. Clinical and survival data were collected, and Kaplan-Meier curves were generated. Odds ratios (ORs) evaluated the presence of FGD1 -SV on brain and bone metastases, while hazard ratios (HRs) assessed association with cabozantinib response. Of 1,037 RNA-seq samples, 84 were metastatic tumor specimens. The relationship between FGD1 -SV positivity and metastasis to common sites was assessed with Fisher's exact test. Results: Brain and bone metastases demonstrated the highest FGD1 -SV positivity (50% and 44%, respectively). A grouped comparison of brain and bone metastases versus all other common metastatic sites (adrenal, lymph node, pancreas, lung, and liver) revealed significant enrichment of FGD1 -SV in these metastases (OR 5.33, 95% CI [1.64 - 18.42], p=0.002). FGD1 -SV positivity in primary tumors was associated with greater risk of recurrence after surgical resection (p=0.0029). Furthermore, FGD1 -SV positive tumors were associated with poor survival when not treated with cabozantinib (HR 2.04, 95% CI [1.20 - 3.45], p=0.01). Conclusions: FGD1 -SV positivity is significantly associated with brain and bone metastatic organotropism in ccRCC. Our findings warrant prospective studies to validate these results and investigate the integration of FGD1 -SV into clinical decision-making, potentially guiding surveillance and therapeutic approaches in high-risk and metastatic patients.

Yeast-derived volatiles orchestrate an insect-yeast mutualism with oriental armyworm moths

Nature Communications Baiwei Ma, Hetan Chang, Mengbo Guo et al. Feb 10, 2025 DOI: 10.1038/s41467-025-56354-3

Lenvatinib plus tislelizumab as first-line therapy for advanced fumarate hydratase-deficient renal cell carcinoma: A single-center, single-arm, phase II study.

Journal of Clinical Oncology Wen Kong, Guangyu Wu, Yunze Xu et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.443

443 Background: Fumarate hydratase-deficient renal cell carcinoma (FH-RCC) is a rare and aggressive subtype of RCC with dismal prognosis. Although bevacizumab plus erlotinib (Beva/Erlo) showed promising anti-tumor activity, treatment option was limited. Date from our retrospective study showed comparable response rates between tyrosine kinase inhibitors plus immune checkpoint inhibitors (TKI/ICI) and Beva/Erlo, while the TKI/ICI group had better overall survival. Here, we reported the preliminary result of an investigator-initiated phase II study evaluating lenvatinib plus tislelizumab for advanced FH-RCC in the first-line setting. Methods: Eligible patients were aged 18-80 years old, diagnosed with pathologically confirmed, unresectable advanced or metastatic FH-RCC, had measurable disease defined by RECIST 1.1 and no history of systemic therapy. A definitive diagnosis of FH-RCC was confirmed when germline or somatic FH mutations were detected via DNA sequencing. All eligible patients received concurrent therapy with lenvatinib 20 mg P.O. daily and tislelizumab 200 mg intravenously every 3 weeks until disease progression, intolerable toxicity, or withdrawal of consent. The primary end point was objective response rate (ORR). Secondary end points included disease control rate (DCR), progression-free survival (PFS), duration of response (DOR), 1-year and 2-year overall survival (OS) rate, and safety. Results: From September 2023 to October 2024, 17 patients were enrolled (male: 14, female: 3). The median age was 37 (24-61). FH germline alteration was identified in 12 patients, while the remaining 5 patients were considered carrying somatic biallelic FH mutations. Thirteen patients had a history of nephrectomy. The most common site of recurrence or metastasis was retroperitoneal space (14/17, 82.1%), followed by bone metastasis (9/17, 52.9%). The median follow up was 7.0 (1.0-12.0) months. Fifteen patients were available for efficacy assessment at data cutoff,fourteen of them had an objective response (ORR 93.3%), and the complete response rate was 20.0% (3/15). The median time to response was 6 weeks. One PFS and OS event occurred. Median PFS and OS were not reached, while 6-month PFS and OS rate were 93.3% and 100% respectively. All grades and ≥G3 AE occurred in 16 (94.1%) and 4 patients (23.5%) respectively. Treatment discontinuation or dosage reduction occurred 8 patients (47.1%). Conclusions: Lenvatinib plus tislelizumab combination showed encouraging anti-tumor efficacy and acceptable toxicity profile. The potential of TKI/ICI/ combination to be recommended as the first-line therapy in advanced FH-RCC patient needs further evaluation. Clinical trial information: NCT05877820 .

The role of cytoreductive radical prostatectomy in the management of patients with metastatic hormone-sensitive prostate cancer.

Journal of Clinical Oncology Axel Heidenreich, David Pfister, Pia Paffenholz et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.157

157 Background: Cytoreductive radical prostatectomy (cRP) has emerged as an alternative treatment option to radiation therapy in men with low risk metastatic hormone sensitive prostate cancer (mHSPC). It was the purpose of our analysis to evaluate if different combinations of androgen deprivation therapy have an impact on pathohistological findings and oncological outcome in men undergoing cRP. Methods: We performed a retrospective analysis of 104 patients who underwent cRP and pelvic lymph node dissection for low volume mHSPC. Prior to cRP, all patients underwent at least 6 months of neoadjuvant systemic therapy with ADT (n=15, 14.4%), ADT + Abi (n=26, 25%), ADT+Apalutamide (n=37, 35.6%), ADT+enzalutamide (n=10, 9.6%), ADT+docetaxel (n=18, 17.3%). We analyzed pathohistology of the cRP and lymphadenectomy specimens and we assessed cancer specific survival (CSS), progression-free survival (PFS), metastatic PFS and overall survival (OS). In addition, surgery related complications and continence were assessed. Results: Mean age was 63 (45-76) years. Median follow-up was 62.1 (2-186) months. Median initial PSA and median PSA at time of surgery was 110 (25-465) ng/ml and 1.25 (&lt;0.01-5.6) ng/ml, resp. Pathohistology of the total group revealed pT0 in 5 (4.8%) pts and pT2a-c, pT3a/b in 16(15.4%) and 83 (79.8%), resp. Pathohistology depending on the type of ADT is given in table 1. pN+ was observed in 45 (43.2%) patients with 1-19 positive lymph nodes and positive surgical margins were identified in 36 (34.6%). Local recurrence was observed in 2 (1.9%) pts. We observed Clavien-Dindo grade III-IV complications in 16 (15.4%) patients. With regard to continence, no, mild (1-2 pads/day) or severe incontinence was observed in 67.7%, 18.2%, and 14.1%, resp. Median OS was 84 months, median clinical progression free survival was 72 months. Conclusions: Based on our data, 75% of patients demonstrate viable and significant prostate cancer despite optimal PSA response to combined neoadjuvant ADT making this a strong argument for local surgical treatment in well selected patients with mHSPC. ADT/apalutamide and ADT/docetaxel are associated with the lowest risk of lymph node metastases making this the preferrable combination. Analysis of CSS, OS and PFS are under way to assess if those findings translate into superior oncological outcome. Surgery related side effects are low if cRP is performed in experienced hands. cRP should be discussed as one option of local treatment in multidisciplinary tumor boards. Pathology dependent on type of ADT. n pT0n (%) pT2a/bn (%) pT2cn (%) pT3a/bn (%) pN+n (%) R1n (%) ADT 15 1 (0.7) 0 2 (13.3) 12 (75) 9 (60) 5 (33.3) ADT + Abi/Pred 26 1 (0.4) 1 (0.4) 3 (11.5) 21 (80.8) 13 (50) 11 (42.3) ADT + Apalutamide 37 2 (0.5) 2 (0.5) 5 (13.5) 27 (73) 7 (19) 7 (19) ADT + enzalutamide 8 0 1 (0.12) 0 7 (87) 6 (75) 3 (37.5) ADT + docetaxel 18 1 (0.5) 1 (0.5) 1 (0.5) 15 (83.3) 7 (38.9) 9 (50)

Metastatic renal cell carcinoma (mRCC) primary refractory patients to first-line IO-TKI and IO-IO combinations (Meet-URO 33 analysis).

Journal of Clinical Oncology Davide Bimbatti, Alessio Signori, Sebastiano Buti et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.499

499 Background: Immune-combinations have become the cornerstone of the mRCC treatment scenario, but direct comparisons between the different first-line therapeutic strategies are lacking and few real-world data are available in this setting. In this context, little evidence is available on those patients with disease progression as best response (primary refractory), who have very poor prognosis and lower possibility to receive further therapies compared to the overall population. Methods: The Meet-URO 33 study is an Italian retrospective/prospective registry of the first-line setting of mRCC patients from January 2021 (Trial registration: CESC IOV 2023-78, PMID: 38914928) with the aim to answer as many clinical questions as possible. This analysis focused on assessing the baseline clinical characteristics and the survival outcomes of mRCC primary refractory patients to first-line immune-combinations. Results: Among 892 patients enrolled from 40 Italian centres, 166 (13%) primary refractory patients were assessed: 37 (31.9%) received IO-IO combination, 68 (58.6%) received IO-TKI combinations and 11 (9.5%) received TKI. After a mFUP of 6.9 months (mo), mPFS was 2.8 mo and mOS 8.2 mo, with no differences in terms of IO-TKI vs IO-IO combinations (HR for PFS = 0.75, p=0.17; HR for OS = 1.06, p=0.81). According to baseline clinical characteristics, compared to other patients, primary refractory patients have a worse IMDC score (favorable-risk: 7.1% vs 23.8%, poor-risk: 36.3% vs 18.6%, p&lt;0.001), Meet-URO score (group 1: 7.5% vs 19.5%, group 5: 12.9% vs 6.4%, p&lt;0.001) and performance status (ECOG PS 2-4: 19.8% vs 7.9, p&lt;0.001); a higher use of steroids pre-first line therapy (11.2% vs 6.2%, p=0.046); a lower percentage of nephrectomy (50% vs 65.3%, p=0.001), clear cell histology (75% vs 83%, p=0.037) and sarcomatoid features (51.7% vs 58.3%, p=0.066); a higher percentage of lung (69% vs 56.1%, p=0.09), lymph node (55.2% vs 43.4%, p=0.018) and bone metastases (38.8% vs 27.8%, p=0.016); a lower percentage of pancreatic metastases (4.3% vs 9.3%, p=0.076). Primary refractory patients received a higher percentage of IO-IO combination (31.9% vs 19.3%) and a lower percentage of TKI (9.% vs 20.6%) compared to the other patients (p&lt;0.001). Conclusions: These preliminary analyses of the ongoing Meet-URO 33 study show distinct baseline clinical characteristics of primary refractory mRCC patients to current first-line immune-combinations. No survival differences were recorded according to the type of immune-combination (IO-TKI vs IO-IO). A longer follow-up and further enrolment are needed to examine in depth the different performance of immune-combinations in primary refractory mRCC patients.

Impact of site of metastatic involvement on IMDC classification in metastatic renal cell carcinoma patients treated with immunotherapy.

Journal of Clinical Oncology Laia Fernandez-Mañas, Irene Ortiz, Javier Pozas et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.483

483 Background: The IMDC risk classification is indispensable for managing metastatic renal cell carcinoma (mRCC) patients (pts). However, it was not developed for pts treated with immunotherapy (ICI) and lacks certain clinically relevant prognostic factors. We aim to explore whether the site of metastatic (SM) involvement can improve prognostic accuracy, as organotropism may be dictated by the underlying tumor's biology. Methods: This multicenter retrospective study analyzed ICI-treated mRCC pts from 2015 to 2023. Overall survival (OS) and progression-free survival (PFS) were evaluated using Kaplan-Meier and multivariate Cox regression analyses. We developed a new score, IMDC-SM, by incorporating SM independently associated with OS into the IMDC classification. Model fitness was assessed using the AIC and BIC. Results: 525 pts were enrolled (73% male, 87% clear cell RCC, 10% with sarcomatoid dedifferentiation), including 191 (36.4%) pts treated in first line (1L). Among pts in 1L and ≥2L, 25% and 18%, 56% and 60%, and 25% and 22% were classified as favorable risk (FR), intermediate risk (IR), and poor risk (PR) by IMDC, respectively. In 1L cohort, most pts were treated with ICI + ICI (56%) and ICI + tirosine kinase inhibitors (38%). 70% of pts had lung involvement, 50% nodal, 29% bone, 20% adrenal, 17% liver, 16% tumoral thrombosis, 9% pleural, 9% peritoneal carcinomatosis, and 7% pancreatic involvement. Pleural, bone, and adrenal metastases were independently associated with worse OS in the multivariate analysis after adjusting for IMDC classification, age, sarcomatoid or rhabdoid dedifferentiation and histology. These SM were incorporated into the IMDC, adding 1 point for each SM present, to create the IMDC-SM score. Using the IMDC-SM, in 1L setting, 16 pts (8%) were reclassified from FR to IR and 28 pts (15%) from IR to PR Results of mOS and mPFS in 1L using both scores are shown in the table. IMDC-SM demonstrated better performance than the original IMDC classification for both in OS (Table). Within PR pts, those with ≥5 points had the worst mOS and mPFS (7 and 5.8m) than the remaining PR pts (24 and 14m). When applying the SM-IMDC in ≥2L pts 31 (9%) were reclassified from FR to IR, 66 pts (20%) from IR to PR and 1pt (0,2%) risk changed from FR to PR. The IMDC-SM classification also shows a superior prognostic value (Table). Conclusions: Combining site of metastasis information with the IMDC classification into a single scoring system significantly improves prognostic accuracy in ICI-treated mRCC pts, in both 1L and 2L. A validation cohort is necessary to determine a prediction model’s reproducibility. Group Risk Score 1L 2L N mOS (m) mPFS (m) N mOS (m) mPFS (m) FR IMDCIMDC-SM 4731 NANA NANA 5927 3748 1015 IR IMDCIMDC-SM 9684 4254 1318 198164 2026 88 PR IMDCIMDC-SM 4876 1521 1212 76142 58 33 OS-AIC IMDCIMDC-SM 691.5686.2 2404.72397.5 OS-BIC IMDCIMDC-SM 696.2690.9 2411.72404.5

Polymerization of proanthocyanidins under the catalysis of miR397a-regulated laccases in Salvia miltiorrhiza and Populus trichocarpa

Nature Communications Caili Li, Xiaoxiao Qiu, Xuemin Hou et al. Feb 10, 2025 DOI: 10.1038/s41467-025-56864-0

Regional and racial disparities in testicular cancer-related mortality among HIV/AIDS adults in the United States and Texas: A 21-year retrospective study (1999-2020).

Journal of Clinical Oncology Sidra Naz, Hira Naz, Kashif Ali et al. Feb 10, 2025 DOI: 10.1200/jco.2025.43.5_suppl.624

624 Background: Men with HIV/AIDS have a significantly higher risk of developing germ cell tumors (GCT), with a notable increase in the incidence of testicular cancer (TC). We aim to study the annual trends and sociodemographic factors in testicular cancer-related mortality in individuals with HIV/AIDS in the United States and its state of Texas from 1999 to 2020 to analyze public health initiatives and to identify areas requiring targeted intervention and prevention strategies. Methods: Mortality trends in TC among HIV/AIDS adults aged ≥25 years were analyzed using CDC WONDER database, identifying through ICD-10 codes C62.9 “Testicular neoplasms” and B20 “HIV/AIDS”. Crude and age-adjusted mortality rates (AAMRs) per 100,000 people were extracted. Annual percent changes (APCs) in AAMRs, with 95% confidence intervals, were determined using joint point regression analysis across various demographic (sex, race/ethnicity, age) and geographic (state, urban-rural, regional) subgroups. Results: Between 1999 and 2020, 89721 documented deaths were attributed to TC due to HIV. The overall AAMR for TC-related mortality in HIV/AIDS adults increased in the US from an adjusted rate (AR) 0.8 in 1999 to (2.9) in 2004 (APC: 4.17%; 95% CI: -2.76% to 38.8%), then it decreased to 1.5 in 2020 (APC: -5.01%; 95% CI: -15.5% to -3.94%). In Texas, AAMR for TC in immunocompromised adults increased from AR 1.5 in 1999 to 3.5 in 2001 (APC: 42.3%; 95% CI: 10.5% to 74.8%), after which it decreased to 1.9 in 2020 (APC: -0.03%; 95% CI: -1.47% to 1.89%). The AAMR in U.S. men increased from 1.4 in 1999 to 4.1 in 2001 (APC: 27.6%; 95%CI: -1.34% to 59.1%) and then decreased to 2.4 in 2020 (APC: -3.99%; 95% CI: -6.09% to -3.27%). The non-Hispanic (NH) Black or African American (AA) (4.9) population has the greatest AAMR, followed by the NH American Indian or Alaska Native (1.9) and the Hispanic or Latino population with AAMR (1.7). The lower-risk population was NH White with AAMR (0.9) and NH Asian or Pacific Islander (0.4). AAMR also varied by region (South: 1.9; Northeast: 1.5; West: 1.3; Midwest: 1) and metropolitan areas had higher AAMR (large central metropolitan: 2.3; large fringe areas: 1.4) than non-metropolitan areas (small metro: 1.1; micropolitan: 1.1; non-core areas: 1.2). The states in the upper 90th percentile of AAMRs were New York, Maryland, South Carolina, Georgia, Florida, Mississippi, Louisiana, and New Jersey exhibited an approximately two-fold increase in AAMRs, compared to states falling in the lower 10th percentile i.e Idaho, Wyoming, Utah, Wisconsin, Minnesota and North Dakota. Conclusions: Mortality rates from testicular cancer among HIV/AIDS adults have declined in the United States and Texas over the past two decades. However, NH Black or AA, NH American Indian or Alaska Native, Hispanic or Latino men are at more risk than NH White and NH Asian or Pacific Islander.